Skip to main content

Table 1 Comparison between baseline and follow-up values of lab investigations of patients

From: Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation

 

Baseline

During treatment

Follow-up

1 month

p value

EOT

p value

3 months

p value

6 months

p value

9 months

p value

Hemoglobin (g/dl)

11.5 ± 0.91

11.2 ± 0.77

0.013

11.4 ± 0.75

0.55

11.3 ± 0.69

0.45

11.3 ± 0.43

0.21

11.1 ± 0.58

0.018

Platelets

153.6 ± 39.4

184.1 ± 59.1

0.003

160.6 ± 36.2

0.43

157.3 ± 38.9

0.69

191.8 ± 36.2

< 0.001

179.7 ± 36.2

0.005

ALT (IU/l)

45.9 ± 15.2

35.8 ± 10.4

0.001

37.6 ± 7.9

0.004

34.3 ± 11.1

< 0.001

33.7 ± 12.4

< 0.001

32.6 ± 11.1

< 0.001

AST (IU/l)

36.8 ± 13.4

35.0 ± 7.1

0.35

33.7 ± 12.4

0.33

36.9 ± 8.6

0.98

38.5 ± 10.5

0.49

37.6 ± 7.9

0.64

AFP (ng/ml)

28.4 ± 17.05

28.9 ± 17.6

0.95

31.4 ± 18.9

0.54

35.3 ± 20.2

0.08

26.6 ± 14.8

0.64

22.6 ± 13.02

0.13

Albumin (g/dl)

3.23 ± 0.39

3.23 ± 0.35

0.49

3.6 ± 0.38

0.001

3.5 ± 0.42

0.019

3.4 ± 0.39

0.04

3.5 ± 0.45

0.004

ALP (IU/l)

132.8 ± 45.1

107.6 ± 11.5

0.002

103.5 ± 48.2

0.002

99.3 ± 14.9

< 0.001

107.6 ± 11.5

0.002

99.3 ± 14.9

< 0.001

Bilirubin (mg/dl)

1.07 ± 0.14

1.03 ± 0.15

0.28

0.99 ± 0.11

0.003

1.3 ± 1.7

0.08

0.99 ± 0.16

0.04

0.99 ± 0.20

0.045

Urea (mg/dl)

45.3 ± 16.9

40.0 ± 10.6

0.18

34.9 ± 10.7

0.005

34.3 ± 9.04

0.001

34.8 ± 7.7

0.005

34.6 ± 7.4

0.002

Creatinine (mg/dl)

0.91 ± 0.33

0.92 ± 0.25

0.99

0.93 ± 0.159

0.72

0.93 ± 0.16

0.52

0.96 ± 0.23

0.43

0.95 ± 0.24

0.65

INR

1.06 ± 0.13

0.92 ± 0.19

< 0.001

1.3 ± 1.6

0.63

0.93 ± 0.19

0.002

1.04 ± 0.14

0.36

1.03 ± 0.22

0.34

  1. EOT end of treatment, ALT alanine aminotransferase, AST aspartate aminotransferase, AFP alpha fetoprotein, ALP alkaline phosphatase